Adherence to treatment guidelines in stage ii/iii rectal cancer in Alberta, Canada

Clinical Oncology

Volumn 24, Issue 1, 2012, Pages

  Eldin, N Sharaf ^a   Yasui, Y ^a   Scarfe, A ^a,b   Winget, M ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b ALBERTA HEALTH SERVICES   (Canada)

Author keywords

Adjuvant treatment; Barriers; Guideline adherence; Healthcare disparities; Neoadjuvant treatment; Rectal cancer

Indexed keywords

ANTINEOPLASTIC AGENT;

AGED; AGING; ARTICLE; CANADA; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER RISK; CANCER STAGING; CANCER SURGERY; CHEMORADIOTHERAPY; COMORBIDITY; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECTUM CARCINOMA; RETROSPECTIVE STUDY;

ADENOCARCINOMA; AGED; ALBERTA; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; DIGESTIVE SYSTEM SURGICAL PROCEDURES; FEMALE; GUIDELINE ADHERENCE; HUMANS; MALE; MEDICAL ONCOLOGY; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM GRADING; NEOPLASM STAGING; PRACTICE GUIDELINES AS TOPIC; RADIOTHERAPY; RADIOTHERAPY, ADJUVANT; RECTAL NEOPLASMS; REFERRAL AND CONSULTATION; SOCIOECONOMIC FACTORS;

EID: 84455199754     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2011.07.005     Document Type: Article

References (47)

1. NIH Consensus Conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990, 264(11):1444-1450. National Institutes of Health.
2. O'Neil B.H., Tepper J.E. Current options for the management of rectal cancer. Curr Treat Options Oncol 2007, 8(5):331-338.
3. Adjuvant radiotherapy for rectal cancer: a systematic overview of 8507 patients from 22 randomised trials. Lancet 2001, 358(9290):1291-1304. Colorectal Cancer Collaborative Group.
4. Sauer R., Becker H., Hohenberger W., et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. NEngl J Med 2004, 351(17):1731-1740.
5. Gunderson L.L., Sargent D.J., Tepper J.E., et al. Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. JClin Oncol 2004, 22(10):1785-1796.
6. Folkesson J., Birgisson H., Pahlman L., Cedermark B., Glimelius B., Gunnarsson U. Swedish rectal cancer trial: long lasting benefits from radiotherapy on survival and local recurrence rate. JClin Oncol 2005, 23(24):5644-5650.
7. Roh M.S., Colangelo L.H., O'Connell M.J., et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. JClin Oncol 2009, 27(31):5124-5130.
8. Wong R.K., Berry S., Spithoff K., et al. Preoperative or postoperative therapy for stage II or III rectal cancer: an updated practice guideline. Clin Oncol (R Coll Radiol) 2010, 22(4):265-271.
9. Romanus D., Weiser M.R., Skibber J.M., et al. Concordance with NCCN colorectal cancer guidelines and ASCO/NCCN quality measures: an NCCN institutional analysis. JNatl Compr Canc Netw 2009, 7(8):895-904.
10. Potosky A.L., Harlan L.C., Kaplan R.S., Johnson K.A., Lynch C.F. Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer. JClin Oncol 2002, 20(5):1192-1202.
11. McGory M.L., Zingmond D.S., Sekeris E., Bastani R., Ko C.Y. Apatient's race/ethnicity does not explain the underuse of appropriate adjuvant therapy in colorectal cancer. Dis Colon Rectum 2006, 49(3):319-329.
12. Ayanian J.Z., Zaslavsky A.M., Fuchs C.S., et al. Use of adjuvant chemotherapy and radiation therapy for colorectal cancer in a population-based cohort. JClin Oncol 2003, 21(7):1293-1300.
13. Townsley C., Pond G.R., Peloza B., et al. Analysis of treatment practices for elderly cancer patients in Ontario, Canada. JClin Oncol 2005, 23(16):3802-3810.
14. Cree M., Tonita J., Turner D., et al. Comparison of treatment received versus long-standing guidelines for stage III colon and stage II/III rectal cancer patients diagnosed in Alberta, Saskatchewan, and Manitoba in 2004. Clin Colorectal Cancer 2009, 8(3):141-145.
15. Schrag D., Cramer L.D., Bach P.B., Begg C.B. Age and adjuvant chemotherapy use after surgery for stage III colon cancer. JNatl Cancer Inst 2001, 93(11):850-857.
16. Iwashyna T.J., Lamont E.B. Effectiveness of adjuvant fluorouracil in clinical practice: a population-based cohort study of elderly patients with stage III colon cancer. JClin Oncol 2002, 20(19):3992-3998.
17. Jessup J.M., Stewart A., Greene F.L., Minsky B.D. Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation. JAMA 2005, 294(21):2703-2711.
18. Hershman D., Hall M.J., Wang X., et al. Timing of adjuvant chemotherapy initiation after surgery for stage III colon cancer. Cancer 2006, 107(11):2581-2588.
19. Wirtzfeld D.A., Mikula L., Gryfe R., et al. Concordance with clinical practice guidelines for adjuvant chemotherapy in patients with stage I-III colon cancer: experience in 2 Canadian provinces. Can J Surg 2009, 52(2):92-97.
20. Winget M., Hossain S., Yasui Y., Scarfe A. Characteristics of patients with stage III colon adenocarcinoma who fail to receive guideline-recommended treatment. Cancer 2010, 116(20):4849-4856.
21. Fritz A., Percy C., Jack A., et al. International classification of diseases for oncology 2000, World Health Organization, Geneva. 3rd ed.
22. Greene F.L., Page D.L., Fleming I.D., et al. American Joint Commission on Cancer (AJCC) cancer staging manual 2002, Springer, New York. 6th ed.
23. Tucker T.C., Howe H.L., Weir H.K. Certification for population-based cancer registries. JReg Mgmt 1999, 26:24-27.
24. Reducing gaps in health: a focus on socio-economic status in urban Canada 2008, Canadian Institute for Health Information, Canadian Institute for Health Information, Ottowa.
25. Deyo R.A., Cherkin D.C., Ciol M.A. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. JClin Epidemiol 1992, 45(6):613-619.
26. Quan H., Sundararajan V., Halfon P., et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005, 43(11):1130-1139.
27. D'Hoore W., Sicotte C., Tilquin C. Risk adjustment in outcome assessment: the Charlson comorbidity index. Methods Inf Med 1993, 32(5):382-387.
28. Winget M., Turner D., Tonita J., et al. Across-province standardization and comparative analysis of time-to-care intervals for cancer. BMC Cancer 2007, 7:186.
29. Surgery for colorectal cancer in elderly patients: a systematic review. Colorectal Cancer Collaborative Group. Lancet 2000, 356(9234):968-974. Colorectal Cancer Collaborative Group.
30. Iversen L.H., Pedersen L., Riis A., Friis S., Laurberg S., Sorensen H.T. Age and colorectal cancer with focus on the elderly: trends in relative survival and initial treatment from a Danish population-based study. Dis Colon Rectum 2005, 48(9):1755-1763.
31. Latkauskas T., Rudinskaite G., Kurtinaitis J., et al. The impact of age on post-operative outcomes of colorectal cancer patients undergoing surgical treatment. BMC Cancer 2005, 5:153.
32. Devon K.M., Vergara-Fernandez O., Victor J.C., McLeod R.S. Colorectal cancer surgery in elderly patients: presentation, treatment, and outcomes. Dis Colon Rectum 2009, 52(7):1272-1277.
33. Margolin B.H. Test for trend in proportions. Encyclopedia of statistical sciences 1988, 334-336. John Wiley & Sons, New York. S. Klotz, N.L. Johnson (Eds.).
34. Deddens J.A., Petersen M.R. Approaches for estimating prevalence ratios. Occup Environ Med 2008, 65(7):481,501-481,506.
35. Ong S., Watters J.M., Grunfeld E., O'Rourke K. Predictors of referral for adjuvant therapy for colorectal cancer. Can J Surg 2005, 48(3):225-229.
36. Abraham N.S., Gossey J.T., Davila J.A., Al-Oudat S., Kramer J.K. Receipt of recommended therapy by patients with advanced colorectal cancer. Am J Gastroenterol 2006, 101(6):1320-1328.
37. Hershman D.L., Wang X., McBride R., Jacobson J.S., Grann V.R., Neugut A.I. Delay in initiating adjuvant radiotherapy following breast conservation surgery and its impact on survival. Int J Radiat Oncol Biol Phys 2006, 65(5):1353-1360.
38. Winget M., Hossain S., Yasui Y., Scarfe A. Characteristics of stage III colon adenocarcinoma patients who fail to receive guideline-recommended treatment. Cancer 2010, 116(20):4849-4856.
39. Kutner J.S., Vu K.O., Prindiville S.A., Byers T.E. Patient age and cancer treatment decisions. Patient and physician views. Cancer Pract 2000, 8(3):114-119.
40. Townsley C.A., Selby R., Siu L.L. Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. JClin Oncol 2005, 23(13):3112-3124.
41. Neugut A.I., Fleischauer A.T., Sundararajan V., et al. Use of adjuvant chemotherapy and radiation therapy for rectal cancer among the elderly: a population-based study. JClin Oncol 2002, 20(11):2643-2650.
42. Dobie S.A., Warren J.L., Matthews B., Schwartz D., Baldwin L.M., Billingsley K. Survival benefits and trends in use of adjuvant therapy among elderly stage II and III rectal cancer patients in the general population. Cancer 2008, 112(4):789-799.
43. Yee K.W., Pater J.L., Pho L., Zee B., Siu L.L. Enrolment of older patients in cancer treatment trials in Canada: why is age a barrier?. JClin Oncol 2003, 21(8):1618-1623.
44. Sauer J., Sobolewski K., Dommisch K. Practical neoadjuvant and adjuvant therapies for rectal cancer. How many patients are actually recruited in multimodality therapy concepts? An analysis of the tumour centre Schwerin. Zentralbl Chir 2009, 134(5):450-454.
45. Weiss J., Moghanaki D., Plastaras J.P., Haller D.G. Improved patient and regimen selection in locally advanced rectal cancer: who, how, and what next?. Clin Colorectal Cancer 2009, 8(4):194-199.
46. Mannion R., Goddard M. Public disclosure of comparative clinical performance data: lessons from the Scottish experience. JEval Clin Pract 2003, 9(2):277-286.
47. Robinowitz D.L., Dudley R.A. Public reporting of provider performance: can its impact be made greater?. Annu Rev Public Health 2006, 27:517-536.